Navigation Links
Morphotek®, Inc. Receives Beacon Award From CancerCare
Date:4/6/2011

EXTON, Pa., April 6, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it was recently awarded the Beacon Award from CancerCare, a national support services organization for people affected by cancer, for its support of CancerCare's educational programs for people facing lung and ovarian cancers.  The two organizations have been working together to help patients and their families become aware of options available to help treat and manage these diseases.  The award was presented at CancerCare's 28th Annual "Partnership in Hope" Dinner in New York City.

"We are honored to be recognized by CancerCare for our team's efforts in working closely with advocacy groups and patients to better understand how to better meet the clinical and emotional needs of patients with cancer," said Nicholas Nicolaides, President and Chief Executive Officer at Morphotek. "Our efforts reflect the philosophy of our team, instilled by our parent company, Eisai, whose human healthcare (hhc) mission is to pursue drug development that satisfies unmet medical needs in a manner that improves the well-being of patients worldwide. This award endorses our efforts in pursuing this mission."

"Morphotek's commitment to innovation cannot be understated," said CancerCare's Chief Executive Officer, Helen H. Miller. "We are grateful to Morphotek for their continued support of CancerCare's free educational programs, as it is vital for people affected by cancer to have access to the most up-to-date information about their diagnosis and its treatment options."

As part of its human healthcare (hhc) mission, the company seeks to proactively learn about the underlying causes of diseases and available approved/experimental therapies. Additionally, the company seeks to learn the patients' thoughts about their disease and treatments by working with key opinion leaders and patient advocacy groups.  This information is shared regularly throughout the company to improve development strategies to identify new therapeutic agents and/or treatment regimens to facilitate patient care.  

About MorphotekMorphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology.  The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications.  The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.  For more information, please visit www.morphotek.com.

About Eisai Inc.Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales).  The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business.  Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com.Contact:Media Inquiries

Media Inquiries

Investor InquiriesTerry Cushmore

Lynn Kenney

Alex ScottMorphotek, Inc.

Eisai Inc.

Eisai Inc.610-423-6197

201-746-2294

201-746-2177tcushmore@morphotek.com

lynn_kenney@eisai.com

alex_scott@eisai.com
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues
2. Cellectis Receives Payment for License to Homologous Recombination Patents
3. China-Biotics Receives First U.S. Sales Order
4. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
5. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
6. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
7. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
8. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
9. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
10. Rensselaer professor Daniel Lewis receives NSF CAREER Award
11. Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):